Close

Moleculin Biotech (MBRX) Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme

Go back to Moleculin Biotech (MBRX) Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme

Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme

December 7, 2022 8:45 AM EST

HOUSTON, Dec. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation of WP1122 for the treatment of Glioblastoma Multiforme ("GBM"). The FDA's Fast Track designation is intended to potentially facilitate the development and expedite the review of novel therapies to treat serious... More